Compare Cintas Corporation (CTAS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Novo Nordisk A/S — how do they compare? Cintas Corporation trades at $204.63 (market cap $82.15B), while Novo Nordisk A/S trades at $46.24 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Cintas Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CTAS | NVO | |
|---|---|---|
Market Cap | $82.15B | $207.85B |
Sector | Industrials | Health |
52-Week High | $225.10 | $63.98 |
52-Week Low | $163.55 | $35.29 |
Enterprise Value | $84.56B | $222.55B |
Dividend Yield | 1.01% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTAS trades at $203.06, showing modest daily gains. The stock exhibits a bullish technical trend, supported by recent earnings beats and strong profitability metrics, including a 17.75% net income margin. Recent news highlights dividend declarations and positive analyst upgrades following Q4 2026 results.
The outlook is positive, with revenue growth and margin expansion driving upside potential toward the $225.83 consensus price target. Risks include elevated valuation multiples and macroeconomic sensitivity. Institutional activity shows mixed positioning, but overall sentiment leans bullish.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
